• RI - Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
    • português (Brasil)
    • English
    • español
  • Sobre
    • RI Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
  • English 
    • português (Brasil)
    • English
    • español
    • português (Brasil)
    • English
    • español
  • Login
View Item 
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • EPM - Outras produções
  • View Item
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • EPM - Outras produções
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: the 2010 GLADAOF Lecture

Thumbnail
View/Open
WOS000306790100022.pdf (4.608Mb)
Date
2011-01-01
Author
Fernando Arevalo, J.
Sanchez, Juan G.
Lasave, Andres F.
Wu, Lihteh
Maia, Mauricio [UNIFESP]
Bonafonte, Sergio
Brito, Miguel
Alezzandrini, Arturo A.
Restrepo, Natalia
Berrocal, Maria H.
Saravia, Mario
Farah, Michel Eid [UNIFESP]
Fromow-Guerra, Jans
Morales-Canton, Virgilio
Type
Resenha
ISSN
2090-004X
Is part of
Journal of Ophthalmology
DOI
10.1155/2011/584238
Metadata
Show full item record
Abstract
This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter interventional comparative case series of intravitreal injections of 1.25 or 2.5 mg of bevacizumab for DME, PDR without tractional retinal detachment (TRD), and patients who experienced the development or progression of TRD after an intravitreal injection of 1.25 or 2.5 mg of bevacizumab before vitrectomy for the management of PDR. the results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse DME. Therefore, in the future this new therapy could complement focal/grid laser photocoagulation in DME. in PDR, this new option could be an adjuvant agent to panretina photocoagulation so that more selective therapy may be applied. Finally, TRD in PDR may occur or progress after IVB used as an adjuvant to vitrectomy. Surgery should be performed 4 days after IVB. Most patients had poorly controlled diabetes mellitus associated with elevated HbA1c, insulin administration, PDR refractory to panretinal photocoagulation, and longer time between IVB and vitrectomy.
Citation
Journal of Ophthalmology. New York: Hindawi Publishing Corporation, 13 p., 2011.
Sponsorship
Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela
URI
http://repositorio.unifesp.br/handle/11600/33206
Collections
  • EPM - Outras produções [3595]

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsBy Submit DateThis CollectionBy Issue DateAuthorsTitlesSubjectsBy Submit Date

My Account

Login

Statistics

View Usage Statistics

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV